ArticleDermatology and therapy2025
Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02260986 (A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionItch control is an important treatment goal for patients with atopic dermatitis (AD). According to the treat-to-target framework, optimal treatment goals in AD were defined for various disease domains (e.g., achievement of Eczema Area and Severity Index [EASI] ≤ 7, Peak Pruritus Numeric Rating Scale [PP-NRS] ≤ 4, and Dermatology Life Quality Index [DLQI] ≤ 5) to be achieved after 6 months and sustained thereafter.
methodsIn this post hoc analysis of LIBERTY AD CHRONOS (NCT02260986), we report the proportion of patients achieving an optimal itch response with or without an optimal response in signs (EASI ≤ 7) and quality of life (DLQI ≤ 5), after 24 and 52 weeks of treatment with dupilumab.
resultsThe majority of patients (69 of 90; 76.7%) had an optimal itch response at week 24 as measured by treat-to-target goal PP-NRS ≤ 4; this proportion was sustained at week 52 (64 of 79; 81.0%). Using SCORing Atopic Dermatitis (SCORAD) Pruritus Visual Analog Scale (VAS) < 4 as validation, the majority of patients (76/89; 85.4%) had an optimal itch response at week 24, and this proportion was also sustained at week 52 (69 of 79; 87.3%). Around 70% of patients with an optimal itch response according to PP-NRS or SCORAD Pruritus VAS also had optimal response in EASI and DLQI at weeks 24 and 52.
conclusionDupilumab provided optimal itch response and further optimal treatment response in signs and quality of life at week 24, sustained up to 52 weeks, in the majority of patients. Graphical Abstract available for this article.
trial registrationNCT02260986.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.